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Purpose: Vascular reconstructions are prone to fail as a result of  the development of  
stenotic lesions, which have historically been attributed to myointimal hyperplasia. In 
animal models, these lesions are associated with marked proliferative smooth muscle cell 
(SMC) response to vascular injury. However, recent studies using sensitive immunocyto- 
chemical techniques in human lesions have generally failed to detect significant cellular 
proliferation. To clarify the role of  cellular proliferation in humans, we characterized the 
cellular composition and proliferative index of  14 early infrainguinal vein graft stenoses. 
Methods: All infrainguinal vein grafts at our institution are prospectively enrolled in a 
duplex surveillance protocol, the details of  which have been previously reported. Among 
98 grafts placed within the last year, 11 patients were identified with 14 progressive, 
focal, high-grade lesions that met previously established threshold criteria for prophylac- 
tic revision to prevent graft thrombosis. Lesions were first detected from 1 week to 7 
months after surgery and were removed and replaced with segmental interposition grafts 
(1.5 to 10 months). Freshly excised lesions were placed in Methyl Carnoy's fixative, 
paraffin embedded, and serially sectioned. The cellular composition of  each lesion was 
determined with cell-specific immtmochemical reagents: ot SMC actin, von Willebrand 
factor (endothelial cell), CD 68 (macrophage), and CD 45RB (monocyte). Actively 
proliferating cells were identified using antibody to proliferating cell nuclear antigen 
(PCNA). The identity of  PCNA-positive cells was determined by double-label immuno- 
cytochemical staining, and the proliferative index (PCNA-positive cells/total cells x 
100) was calculated by computer-assisted counts of  representative gridded cross-sections 
of  each lesion. 
Results: All excised lesions demonstrated marked thickening with severe luminal en- 
croachment and were highly cellular, with a predominance of ot SMC actin +. Endothelial 
cells on the blood flow surface were present to a variable degree, and seven lesions 
exhibited striking numbers of  macrophages and monocytes. The latter cell types were 
most abundant near microvessels in the deep neointima nd adventitia. Active cellular 
proliferation was identified primarily in SMCs, with a mean PCNA index of 1.34%. 
However, significant PCNA reactivity was not limited to SMCs, but was also identified in 
macrophages and monocytes, particularly in lesions greater than 3 months old. 
Conclusions: Previous immunocytochemical studies of  human coronary restenosis 
atherectomy specimens have generally detected low rates of  cellular proliferation (0.5%), 
but these lesions may not tnfly represent myointimal hyperplasia, rather a mixture of  
atherosclerosis, thrombosis, and "restenosis." In contrast, the present study of  early 
human vein graft lesions detected by duplex surveillance indicates that significant cellular 
proliferation occurs, although rates are lower than those obtained in animals such as the 
rat carotid injury model. In addition, although SMCs are the predominant proliferating 
cell type in human vein grafts, our identification of  proliferating monocytes and macro- 
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phages raises the question of  the contribution of an inflammatory component o the 
development of human lesions. The present study represents the first report of  PCNA 
determination in a series of human infrainguinal vein grafting procedures. (J Vasc Surg 
1997;25:64-73.) 
Autogenous saphenous vein remains the conduit 
of choice for lower extremity arterial bypass grafts; 
however, its long-term patency is compromised be- 
cause of the development of vein graft stenosis. Ap- 
proximately 20% to 30% of inftainguinal vein grafts 
develop hemodynamically significant stenosis that, if 
not repaired, threatens the patency of the graft. 1-a 
Vein graft stenosis has long been attributed t O the 
process of myointimal hyperplasia or myointimal 
thickening (MIT). Theories concerning the patho- 
genesis of MIT have been largely developed from 
research using balloon arterial injury in animal mod- 
els as well as studies of restenosis after coronary 
angioplasty in humans. 4 Apparent differences regard- 
ing the rate of cellular proliferation have been ob- 
served in different vascular lesions in humans and 
animals. Although igh cellular proliferation rates are 
detected early after balloon injury in the rat carotid 
artery model, 5 limited studies of human vascular le- 
sions have generally revealed a low rate of cellular 
proliferation, less than 2% in coronary atherectomy 
specimens. 6 However, most of the current informa- 
tion regarding human lesions was derived from stud- 
ies performed on tissue specimens that were recov- 
ered during atherectomy; the results obtained from 
such samples may be difficult to interpret because 
they represent a mixture of atherosclerosis, throm- 
boric events, and restenosis. To date, stenotic lesions 
that develop in vein grafts that are used in coronary 
and peripheral arterial bypass procedures have not 
been extensively studied. The development ofduplex 
scanning and its application to serial postoperative 
surveillance of infrainguinal vein grafts affords the 
oppommity for the early detection of graft-threaten- 
ing lesions and their correction or removal before the 
occurrence of graft occ lus ion .  7-9 
The purpose of the present study was to deter- 
mine the cellular composition and degree of cellular 
proliferation associated with human vein graft ste- 
notic lesions to elucidate part of the cellular mecha- 
nisms involved in their development. 
METHODS 
All patients who underwent infrainguinal utog- 
enous vein graft reconstruction for atherosclerofic 
occlusive disease at the University of Arizona Medi- 
cal Center and the Tucson Veterans Administration 
Medical Center are prospectively observed by an es- 
tablished serial duplex surveillance protocol. 9d° Du- 
plex scans and Doppler-derived ankle-brachial index 
measurements are performed on each patient at 1 
and 6 weeks, then 3, 6, 9, 12, 18, and 24 months 
after graft implantation. The entire graft and adja- 
cent native arteries are imaged using color-flow du- 
plex scanning (CFDS) to identify and grade flow 
disturbances according to well-established crite- 
ria. 9a° Graft lesions that progress to a Vp (peak 
systolic graft velocity) greater than 300 cm/sec or an 
increased velocity in an area of stenosis uch that the 
ratio of the peak velocity to the velocity proximal to 
the stenosis (Vr) is greater than 3.5 (Fig. 1, A) are 
prophylactically repaired to prevent graft occlusion. 
The presence and degree of stenosis identified by 
duplex surveillance is confirmed angiographically 
when clinically indicated (Fig. 1, B). Surgical revision 
consists either of partial excision and vein patch an- 
gioplasty or, if it is circumferential, excision of the 
entire lesion and replacement with a new autogenous 
vein segment, n 
Over the past year, 14 vein graft lesions were 
observed in 11 patients at the time of revision for 
high-grade stenosis. There were seven men and four 
women with a mean age of 70 years (range, 46 to 88 
years). Risk factors included systemic hypertension i  
seven patients, diabetes mellitus in five, coronary 
artery disease in six; three patients had hyperlipid- 
emia, and six had a smoking history. No patient had a 
history of chronic renal failure or of a hypercoagu- 
lable state. The surgical indications were limb salvage 
in seven patients and severe claudication i  five oth- 
ers. Ipsilateral greater saphenous vein was used in 
seven patients (three in situ, four reverse). Spliced 
vein conduits were used in three patients (greater and 
lesser saphenous veins in one patient and greater 
saphenous and arm vein in two). One conduit con- 
sisted of a composite sequential graft using expanded 
polytetrafluoroethylene (e-PTFE) and lesser saphe- 
nous vein. The proximal anastomosis was to either 
the common femoral bifurcation or the superficial 
femoral artery. The distal anastomosis was to the 
above-knee popliteal evel in one case, the below- 
knee popliteal level in four, the anterior tibial artery 
in one, the posterior tibial artery in one, and the 
peroneal artery in four cases. 
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Fig. 1. A, Duplex scan-derived peak systolic graft flow velocity and markedly elevated dia- 
stolic velocity obtained at site of a vein graft stenotic lesion. Also note wide spectral broadening. 
B, Arteriogram shows corresponding focal distal juxtaanastomotic lesion. 
The subsequent lesions were all removed within 
1.5 to 10 months after implantation. Three patients 
had a second lesion removed at the time of surgical 
revision. There were five proximal lesions, two midg- 
raft lesions, and seven distal esions. The mean peak 
systolic velocity by CFDS just before the time of 
surgical revision was 460 cm/sec, with a velocity 
ratio varying from 3.1 to 10.8. The freshly excised 
stenotic specimens were immediately placed in 
Methyl Carnoy fi afive for 24 to 48 hours. Depend- 
ing on the length of the specimen obtained, one to 
three cross-sectional slices were obtained and placed 
in separate paratfin-embedded blocks with the loca- 
tion of each cut section relative to the location of the 
most stenotic site carefully recorded. In each block 
the sample was placed vertically and oriented from 
proximal to distal with respect o direction of blood 
flow. Serial 5 t~m-thick sections were obtained and 
placed on glass slides. The general morphologic fea- 
tures of the different lesions were assessed using he- 
matoxylin & eosin and Masson's trichrome stain. 
Single-label immunocytochemistry. Immuno- 
peroxidase labeling for the proliferating cell nuclear 
antigen (PCNA) was used to determine the degree of 
cellular proliferation in each lesion. First sections 
were deparalfinized with xylene and rehydrated in 
graded ethanol series. The sections were then briefly 
microwave-heated in a citrate buffer solution (pH 
6.6). After blocking endogenous peroxidase activity 
with 3% H202, the primary antibody (PC 10 Immu- 
noglobulin IgG, Dako Corp., Carpinteria, Calif.) 
was applied at a 1:150 dilution for 30 minutes at 
room temperature. A biotinylated secondary anti- 
body was then applied for 15 minutes, followed by a 
streptavidin peroxidase conjugated (Dako Corp.) for 
15 minutes at room temperature. Slides were ex- 
posed to 3,3' diaminobenzidine (DAB) to obtain a 
brown reaction product. Counterstaining wasper- 
formed with hematoxylin and completed bydipping 
the slides in a bath of 37 mmol ammonia water. 
For each PCNA immunocytochemistry run, a 
standard of known hyperproliferative nature (rat 
small intestine) was included as a control. Two sepa- 
rate sections of rat small intestine were simulta- 
neously run as controls: one was exposed to the 
anti-PCNA antibody (positive control), the other 
one was similarly run except hat the primary anti- 
body was not used (negative control), the latter to 
insure that no false-positive staining was occur- 
ring. In the positive control slides, whereas the 
intestinal crypt cells were PCNA-positive, the mus- 
cle cells in the muscular layer of rat small intestine 
did not stain positively for PCNA. Labeling was 
considered positive if the nuclei of the intestinal 
crypts were labeled dark red and the nuclei of the 
stenotic lesion stained dark red. Earlier in our 
study, the immunoperoxidase technique was also 
used to determine the nature of the different cell 
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types, using the following primary antibodies 
(made from Dako reagents): anti-s-smooth mus- 
cle actin to identify smooth muscle cells (SMCs), 
anti-CD68/CD45RB to identify monocytes/mac- 
rophages and anti-human factor VIII related anti- 
gen (vWF) to identify endothelial cells. When it 
was noted that these cell types were constantly 
present in the first five lesions studied, 
identification ofthe proliferating cell type was simulta- 
neously carried out by double-labeled immunocyto- 
chemistry with PCNA and cell-specific markers. 
Double-label immunocytochemistry. Double- 
label immunocytochemistry was performed on tissue 
sections adjacent to the respective section in which 
the highest proliferation rate was encountered for 
each individual lesion. First immunocytochemical lo- 
calization of PCNA was performed as previously de- 
scribed except hat nickel chloride was added to the 
DAB solution to obtain a black, high-contrast, reac- 
tion product. 
The specimens were then extensively washed with 
deionized water and exposed to a second primary 
antibody specific for each particular cell type, as spec- 
ified above. The slides were incubated at room tem- 
perature for 3 hours. A biotinylated secondary anti- 
body to the second primary antibody was then 
applied for 30 minutes, followed by an alkaline phos- 
phatase-labeled r agent (APAAP, Dako)for 30 min- 
utes, and finally a fuchsin chromogen was applied for 
20 minutes to yield a red reaction product at the site 
of the target antigen in the cytoplasm. Here hema- 
toxylin or methyl green counterstain were used to 
visualize the nuclei n the tissue sections. 
Cell counting. The total number of PCNA-pos- 
itive cells per slide was manually counted under light 
microscopy at 400× magnification, with the ob- 
server blinded to the clinical details pertaining to the 
specimens. In each slide, the total number of nuclei 
was also determined using a computer image analysis 
system (Image-1/Metamorph Imaging Systems, 
Universal Imaging Corporation, West Chester, Pa.). 
The ratio of PCNA-positive nuclei to the total num- 
ber of nuclei × 100 yielded a PCNA index for each 
lesion. 
In each double-labeled slide, the number of 
PCNA-positive cells was also counted manually to 
determine both the total number of PCNA-positive 
nuclei per section and the number of cells that la- 
beled for PCNA and for a specific cell-identity 
marker. Random verification of the manual cell 
counts (AW) were done by a second blinded ob- 
server (JM) to assure that the interpretation of 
PCNA-positive cell was in agreement. 
RESULTS 
General morphologic features. All excised le- 
sions demonstrated marked thickening with severe 
luminal encroachment and were highly cellular (Fig. 
2, A), with a net predominance of ~ SMC actin 
positive cells (Fig. 2, D). Microvessels were present 
to a variable degree within the lesions; they were 
more abundant in the outer layers (Fig. 2, E). Some 
of the specimens exhibited significant numbers of 
inflammatory cells in the thickened neointima (Fig. 
2, F). The extracellular matrix also appeared to be a 
major component of the intimal thickening, as dem- 
onstrated by Masson's trichrome stain (Fig. 2, B). 
PCNA labeling. The majority of the sections 
studied exhibited no evidence of cell replication. 
PCNA-positive nuclei were found in greater num- 
bers in the sections immediately proximal to the area 
of high grade stenosis (Fig. 2, C). The area of highest 
cellular proliferation appeared to occur atthe inflow 
jet just proximal to the site of maximal stenosis. The 
mean PCNA index was 1.34% + 1.48%, with the 
highest proliferative rate recorded being 5.2%. 
When the proliferative profile of the vein graft 
samples was plotted as a function of time from the 
initial surgical intervention, o statistical correlation 
could be established. 
Characterization of cell types displaying 
PCNA immunoreactivity. For each specimen, rep- 
resentative s ctions adjacent to those displaying the 
highest degree of PCNA immunoreactivity were an- 
alyzed by double-label immunocytochemistry using 
PC 10 and cell specific markers (Fig. 2, D-F). The 
most prevalent proliferating cell type identified was 
the SMC c~ actin positive: 30.6% + 12.36%; micro- 
vascular endothelial cells represented 27.7% + 
11.1%; monocytes/macrophages totaled 24.95% _+ 
20.69%. A total of 21.0% of proliferating cells were 
not identified by any of the cell-specific markers used. 
DISCUSSION 
Although autogenous vein is the conduit of 
choice for infrainguinal bypass, its use remains 
plagued by the development ofintrinsic graft stcno- 
ses, which develop in 20% to 30% of such conduits, 
usually within 2 years after graft implantation. 2,s
With the advent of CFDS, these lesions can now be 
detected and monitored for progression by serial 
CFDS surveillance. When lesions progress to prede- 
termined threshold values, usually based on measure- 
ments of peak systolic velocity (Vp) or velocity ratio 
(Vr), prophylactic repair is carried out to prevent 
graft occlusion. TM
Previous data suggest that early flow disturbances 
JOURNAL OF VASCULAR SURGERY 




~i! ~ilil ~ i ~ ~ 
ii ¸  ¸~ii i  ~ 
Fig. 2. Morphologic assessment of human vein graft stenoses by hematoxylin and eosin 
(H&E), Masson's trichrome stain; single-label immunocytochemistry with anfi-PCNA, double 
immunolabeling for PCNA and different cell-specific markers. A, Hypercellularity noted on 
H&E stain with severe luminal narrowing (original magnification, 3.125 ×). B, Abundant 
extracellular matrix, high collagen content (blue-green), asseen with Masson's trichrome stain 
(original magnification, 12.5 ×). C, Immunocytochemical labeling for PCNA. PCNA-positive 
nuclei appear as dark red and are present in cells adjacent to the residual lumen in this specimen 
(original magnification, 31 x). D, Double immunolabeling for PCNA and c~-smooth muscle 
actin. Here PCNA-positive nuclei appear as dark black (peroxidase reaction, shown with 
arrowhead) and m-smooth muscle actin-positive cytoplasms appear as red (alkaline phosphatase 
reaction). Blue hematoxylin counterstain shows PCNA-negative nuclei (original magnification, 
125 ×). E, Double immunolabeling for PCNA and vWF. Note abundant microvascularity 
within thickened intima. Arrowhead indicates a proliferating endothelial cell (original magnifi- 
cation, 125 ×). F, Double immunolabeling for PCNA and CD68/CD45RB. Arrowhead 
indicates a proliferating inflammatory cell on the left as indicated by a black nucleus and a red 
cell-type-specific protein cytoplasm (original magnification, 125 x). 
detected after graft implantation are a marker for the 
subsequent development of graft stenosis. 7-9 Such 
early flow disturbances may represent preexisting 
conduit abnormalities, residual technical defects, or 
develop de novo at sites of vessel injury. The natural 
history of these flow disturbances has been evaluated; 
it appears that nearly 45% to 50% of these lesions will 
progress during CFDS follow-up and require revi- 
sion, and the remainder will remain stable or actually 
regress. 9 In the present series, flow disturbances were 
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first detected by CFDS between 1 week and 6 
months after surgery, and lesion removal and vein 
graft repair because of stenosis progression was per- 
formed within 1.5 to 10 months. 
On the basis of animal models of arterial response 
to injury, the pathogenesis of intrinsic stenotic le- 
sions after arterial repair or vein graft reconstruction 
has been attributed to myointimal hyperplasia. A
smooth muscle cell hyperproliferative r sponse has 
been thought o be responsible for the rapid growth 
and progression of these lesions. 12 The present study 
using PCNA immunocytochemical analysis of freshly- 
excised human vein graft stenoses uggests that al- 
though cellular proliferation is present and detect- 
able, it seems to occur at a level much lower than that 
reported in the rat arterial injury model. In the latter 
model, cellular proliferation indexes of 30% to 50% 
have been reported in the initial period after the 
injury with persistence but at a lower replication rate 
throughout a 12-week period. 5 In addition, using 
double-label immunocytochemistry to identify the 
specific proliferating cell type, our results indicate 
that cellular proliferation is not confined to SMCs, 
but also occurs in endothelial cells, monocytes, and 
macrophages. These data suggest hat human vein 
graft wall biologic mechanisms may be different from 
animal models. 
Previous reports have questioned the degree to 
which cellular proliferation contributes to the devel- 
opment of either atherosclerotic or myointimal le- 
sions in human beings. Gordon et al. ~3 used PCNA 
to quantify the proliferative index in the coronary 
arteries of hearts explanted from transplant recipi- 
ents; the mean PCNA index in plaque intima was 
only 0.85%, indicating that minimal proliferation was 
occurring. O'Brien et al.6 assessed cellular prolifera- 
tion using PCNA immunocytochemistry in primary 
and restenotic oronary atherectomy tissue in 211 
patients and found low levels of PCNA-positive cells 
(-<1%). Although few early (<60 days) lesions were 
analyzed, no peal< of cellular proliferation was de- 
tected in the restenotic specimens. The report of 
Picketing and associates ~4 conflicts with the observa- 
tions cited above. Using PCNA immunohistochem- 
istry and in situ hybridization to study cellular prolif- 
eration in 19 human restenotic atherectomy 
specimens, they identified PCNA indexes of 15.2 
and 20.6 by the above methods, respectively. The 
explanation for this dramatic difference in results is 
unclear. 
The present study was undertaken because we felt 
that the study of human vein graft lesions that had 
been followed by duplex surveillance, monitored for 
progrcssion, and rcmoved before thrombotic events 
and graft occlusion might yield a collection of my- 
ointimal lesions with anatomically defined character- 
istics for analysis. Angioplasty and restenosis of a 
coronary artery with preexisting atherosclerotic dis- 
ease may result in a very different cascade of events 
than that which occurs after implantation of an au- 
togenous vein into the arterial circulation. The mean 
PCNA index in the 14 human vein graft lesions was 
1.34%, a detectable, significant level, but much lower 
than some animal models would predict. We were 
also unable to correlate the proliferative index with 
the age of the lesion at the time of removal. 
The use of PCNA immunohistochemistry to as- 
sess cellular proliferation is well-established. Gordon 
et al) 3 assessed the sensitivity and specificity of 
PCNA determination i  paraffm-embedded material 
by comparison with in vivo thymidine labeling in rat 
tissues. In the small intesunal crypts, essentially all 
thymidine-positive c lls were also PCNA-positive; 
however, there were five times as many PCNA-posi- 
rive as thymidine-positive c lls, and the overall 
PCNA index was 25.1%. These findings are consis- 
tent with the restriction ofthymidine labeling to cells 
in S phase, while PCNA protein is expressed not only 
in S, but also during the G 1 and G 2 phases of the cell 
cycle. PCNA distinguishes cells that are in the cell 
cycle from those in Go (or quiescent state). PCNA 
staining is thought o be more sensitive than thymi- 
dine labeling for identifying cellular proliferation) 4 
Although c¢ SMC actin-positive cells were the pre- 
dominant cell type in the neointima, their replication 
rate was quite low. This low level of SMC replication 
in human vein graft stenoses uggests that cellular 
proliferation, by itself, does not explain the entire 
process of lesion growth and progression (our time 
frame is actually much longer than animal models). 
Our method of PCNA immunocytochemistry in- 
cluded the use of an antigen retrieval microwave 
heating technique. This technique has been reported 
by others to both enhance the immunostaining sig- 
nal and to obtain greater contrast with the back- 
ground15,16; we have made similar blinded observa- 
tions in our laboratory (unpublished data). McKee et 
al. 17 also noted that the antigen retrieval technique 
by microwave irradiation appears to reduce the inci- 
dence of false-negative staining. 
In addition to assessing the degree of cellular 
proliferation i human vein graft lesions, the second- 
ary purpose of this study was to determine the iden- 
tity of the actively proliferating cells. The application 
of double-label immtmocytochemistry using anti- 
PCNA and cell-type specific markers yielded interest- 
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ing information. Only 30.6% of the actively replicat- 
ing cells were SMC a actin-positive. Endothelial cells 
and monocyte/macrophages accounted for 27.7% 
and 24.9%, respectively, of  the actively proliferating 
cells. These results concur with the data of O'Brien 
and associates, 6 who also identified low numbers of  
PCNA positive SMCs, endothelial cells, and macro- 
phages in coronary atherectomy specimens. 
Previous investigations have noted that pheno- 
typic changes occur in SMCs in response to vessel 
injury; is they may acquire asynthetic state concomitant 
with the onset of cell replication and express extracellu- 
lar matrix genes. 19 Other data suggest hat maximal 
expression of some of these matrix genes may be largely 
limited to quiescent SMCs after a brief period of repli- 
cation. 2° These observations could explain the rela- 
tively rapid growth and progression of human vein 
graft stenoses as a result of matrix production and 
deposition and yet be consistent with the relatively 
low rates of  SMC proliferation we have detected. 
The presence of  endothelial cell proliferation has 
been previously reported in human primary and 
restenotic coronary lesions 6and arteriovenous dialy- 
sis fistulae. 21 The precise contribution of these acti- 
vated endothelial cells to lesion development is as yet 
unknown. Endothelial cell proliferation may be a 
necessary component of  healing after endothelial cell 
injury during vein graft harvesting, preparation, and 
the response to arterialization. The vascular endothe- 
lial cells are under constant hemodynamic forces 
generated by the bloodstream; recent studies have 
revealed that these effects translate in the promotion 
of human platelet-derived growth factor-B chain, a 
known mitogenic and chemotactic factor for 
SMCs. 22 The expression of vascular endothelial 
growth factor (VEGF) and VEGF receptors has been 
correlated with endothelial cell proliferation2S,24; this 
process may be associated with the development of a 
new microvasculature after vein graft implantation. 
Hypoxia has also been shown to be an important 
regulator of VEGF expression. 2s
The presence of a significant number of prolifer- 
ating inflammatory cells in human vein graft lesions 
also raises interesting questions. In autogenous vein 
grafts, the presence of  monocytes and macrophages 
could merely represent a rather nonspecific response 
to injury. It has been reported in animal models of 
atherogenesis that the development of  atheroscle- 
rotic lesions is preceded by the early intimal penetra- 
tion of blood-borne mononuclear cells. 26,27 Al- 
though it is generally thought o take several years 
for vein grafts implanted into the arterial circuit to 
develop atherosclerosis, mononuclear cells could 
play an early role. An additional 21% of actively 
proliferating cells in the vein graft lesions we studied 
could not be identified by any of  the cell markers 
used. These unidentified mesenchymal cells may rep- 
resent SMCs or other cell types at different stages of 
differentiation. There is clearly a need for further 
detailed studies to determine and further character- 
ize the cell type and degree of  proliferation present in 
human lesions at various stages of  development. 
CONCLUSION 
The present study of early human autogenous 
vein graft lesions detected by duplex surveillance 
indicates that although active cellular proliferation is
detectable (mean PCNA index, 1.34%), the degree is 
much less than that obtained in animal models such 
as rat balloon arterial injury. In addition, only ap- 
proximately one third of  actively proliferating cells 
stained for a-smooth muscle actin. The role of pro- 
liferating endothelial cells and inflammatory cells is 
worthy of further investigation. These data may also 
partially explain why therapies targeted specifically 
against SMC proliferation have been generally inef- 
fective in humans. 
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DISCUSSION 
Dr. Alexander W. Clowes (Seattle, Wash.). As the 
investigators have pointed out, stenosis of vein grafts con- 
tinues to be a vexing problem and it has not yet been 
resolved. Hemodynamically significant s enosis develops in 
20% to 30% of grafts, primarily during the first year after 
implantation and, iftmtreated, causes graft thrombosis. It
is therefore of great importance to understand how steno- 
sis develops and then devise strategies to block it. I think 
we are still largely in the first phase of this investigation. 
Dr. Westerband and his colleagues have painstakingly 
studied 14 graft lesions that were completely excised from 
11 patients between 1.5 and 10 months after graft place- 
ment, and they have characterized the specimens by immu- 
nohistochemical analysis. As expected from the results of 
the work of others, the predominant cell type is the vascu- 
lar SMC. In addition, they fotmd some microvessels and 
macrophages, aswell as large amotmts of matrix. What is 
novel in this study is the presence of proliferating cells, 
endothelium, and macrophages, other than the SMCs. I 
think we saw a little of this the other day when Russell Ross 
gave his presentation in which he showed that in the 
primary atherosclerotic lesions we see proliferating macro- 
phages as well as proliferating SMC and endothelium. The 
proliferative index determined by double labeling for 
PCNA and then using, in addition, unique cell markers, 
was approximately 1%, with a maximum being 5%. 
This number may seem low to all of you, but it is in fact 
quite high in comparison with the proliferative indexes in 
normal vessels, which are usually less than 0.1%. In fact, in 
all of you, your SMCs are turning over once every 30 years. 
So these numbers are actually very, very high. In injured 
arteries and vein grafts of animals, cellular proliferation is
an early event that ceases omewhere between 1 and 3 
months. We should anticipate a similar pattern of prolifer- 
ation in the human vein grafts and expect he PCNA index 
to be returning to low levels by the time the lesions need to 
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be treated surgically. On the other hand, matrix synthesis 
and accumulation continue for some time and account for 
the bulk of most injury-induced intimal thickenings. 
I have several questions. First, have you determined 
what proportion of the lesions you have excised is made of 
matrix, and have you any evidence that matrix synthesis i
ongoing during the period 1.5 to 10 months? 
From what part of the lesions did the cells come? Do 
you think that the SMCs came from the media of the vein 
graft, or did they come from the microvessels that have 
actually grown in? 
Third, what started the process? Do you think that the 
small thrombi forming at the time of implantation serve as 
a nidus for later scarring? 
And fourth, is the stenosing process really directly 
related to the intimal hyperplasia, or is it the sum ofintimal 
hyperplasia, vasoconstriction, and vascular remodeling? 
Dr. Alex Westerband. To answer your first question, 
at the present time we can only speculate that the bulk of 
the lesion is matrix, but we have not yet quantitatively 
determined the proportion of matrix in relation to the cell 
content. We tend to believe in the assumption that after a 
period of rapid cellular replication, matrix synthesis and 
accumulation continue. There have been some experimen- 
tal studies to show that quiescent SMCs are primarily 
involved in this process. 
To answer your second question, we have not yet 
determined the origin of the SMCs present within the 
infima. As a first step to elucidate this question, we are in the 
process of calculating the percentage of cellular proliferation 
present in each of the three layers and then we will try to 
establish statistical comparisons of the intimas and the 
medias within the lesion. We also plan to study the migra- 
tion potential of human vascular SMCs within the media. 
To answer your third question, we believe that flow 
disturbances are the initiating process that leads to the 
development ofvein graft stenosis. We do have evidence of 
platelet aggregates atthe site of the stenosis in some spec- 
imens, as we also saw in one of the intraoperative images 
that was presented earlier. 
And to answer your fourth question, we do not believe 
that intimal hyperplasia lone is sufficient o explain the 
entire stenotic process. But as you thoughtfully stated, it is 
a combination of several factors uch as intimal hyperplasia, 
matrix deposition, vasoconstriction, and vascular remodel- 
ing. We think that with a larger collection of vein graft 
stenotic lesions we will be able to characterize precisely the 
three-dimensional p ttern of cellular proliferation because 
this pattern may suggest different distributions of responsi- 
ble regulatory growth factors involved in the development 
of the lesion. 
Dr. James C. Stanley (Ann Arbor, Mich.). Prolifera- 
tive indexes in atherosclerotic plaque, using PCNA label- 
ing, have revealed increased mitoses in areas of neovascu- 
larization, and the latter are most evident in regions of 
necrotic tissue. This raises the question as to whether 
certain cytokines in these tissues are mitogenic in regard to 
mesenchymal cells or angiogenic in regard to endothelial 
cells. Did you note greater numbers ofmonocytes, macro- 
phages, or SMCs about areas of neovascularity? 
Dr. Westerband. Our preliminary Observations were 
that microvascularity was present more predominantly in 
the lesions that developed and progressed early after vein 
graft implantation. In contrast, inflammatory cells were 
mostly present in older, more advanced lesions. 
Dr. Stanley. I understand, but in those areas of greater 
microvascularity was there greater mesenchymal prolifera- 
tion, independent of endothelial cell proliferation? 
Dr. Westerband. Not really at this point. 
Dr. Alun H. Davies (London, United Kingdom). I
would just like to raise a few points with you. We have 
previously well shown that macrophage infiltrates and lym- 
phocyte infiltrates in the vein before bypass usage are 
associated with the development ofvein graft stenosis. And 
it has also been well documented that vein before its use 
has got subendothelial SMCs, and this has also been shown 
by Frank Veith's group. I would be interested in your 
comments as to how you think this all fits together with 
your findings? 
Dr. Westerband. We have been able in many of these 
patients to obtain a segment of normal vein at the time of 
implantation. We have begun to correlate what is present 
in this age-matched vein with the subsequent development 
of different elements within the lesion. There is clear evi- 
dence of SMCs in the subendothelial region of "normal" 
vein. Minimal to no cellular proliferation is detectible in 
the normal, nonarterialized vein. I don't know whether 
that answers your question. 
Dr. Davies. Can I just clarify something? Have you 
actually taken a vein from each of these 91 patients and 
actually looked at those to see how they related to the 
development ofyour stenosis? 
Dr. Westerband. Actually we have not really done 
that, but this should certainly be one of our next steps. 
Dr. Mitchell H. Goldman (Knoxville, Tenn.). This is 
the beginning of a neat study, and I urge you to con- 
tinue studying them. I have two related questions. The 
first one relates to shear stress and flow. Because you 
have a segment of  vein, have you looked along the 
segment proximal and distal to the stenosis to relate 
your PCNA-positive cellularity and also your percentage 
of SMC ingrowth compared with, say, the matrix, to see 
whether there actually is an influence of different areas in 
the vein stenosis that is perhaps related to what we 
perceive as a shear stress effect? 
The other question is have you actually looked at some 
normal, nonstenotic parts of that vein, that you might have 
resected at the time that you were doing the repair? 
Dr. Westerband. We had the opportunity of looking 
at segments of a normal arterialized vein and have seen 
evidence of microvascularity within the intima, significant 
intimal thickening, and predominance of matrix. These 
observations were made by analyzing an arterialized non- 
stenotic vein segment located istal to the stenotic lesion. 
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There were only rare PCNA-positive nuclei present. Most 
PCNA-positive nuclei were detected at the inflow segment 
just proximal to the area of tight stenosis. Distal to the 
lesion we have seen evidence of intimai thickening and a 
predominance of matrix, rare cellular proliferation, 
whereas proximal to the tightest area of stenosis we have 
seen more cellular proliferation and also a significant 
amount of extracellular matrix. 
Dr. Antonio Sterpetti (Rome, Italy). I was wonder- 
ing whether you found any difference in the proliferation 
characteristic of early and late lesions. It could be that in 
the early lesions you have more SMC proliferation, so you 
have features ofintimal hyperplasia. In the late lesions you 
have more macrophage and monocyte proliferation and so 
you have some future atherosclerosis. Could you com- 
ment? 
Dr. Westerband. Yes, this is what our preliminary 
observations suggest. But until we get to study a larger 
collection of lesions, we can only speculate that this 
might be the case. We tend to find more inflammatory 
cells in older lesions, but we also have found inflamma- 
tory cells in early lesions. But there is a trend, as I 
mentioned, that more inflammatory cells are found in 
older lesions. So we are hoping that after reviewing 
more specimens that we will be able to come up with 
some statistical analysis. 
Dr. John R. Hoch (Madison, Wis.). Would you pos- 
tulate for us what you believe the cell types are that com- 
prise the 21% of cells that did not stain for either a actin or 
macrophages or monocytes? Are these cells myofibroblasts 
that may have their origins from another area of the vein 
wall, perhaps the adventitia? 
Dr. Westerband. Yes, we believe that many of these 
unidentified cells could be SMCs at different degrees of 
differentiation. They may not be expressing et actin but 
rather [3 actin. We are in the process of using other mark- 
ers, such as nonmuscle myosin, to try to identify those 
cells. We will also be using some of the other markers that 
Dr. Ross mentioned, such as CD3, to try to detect lym- 
phocytes and other cell types. 
